Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-dependent kinase 1–Cyclin B1 complex (Cyclin B1–CDK1)
- Target
- Cyclin B1–CDK1
- Molecular classification
- Enzyme, Regulatory protein complex, Kinase
01
Overview
The **Cyclin-dependent kinase 1–Cyclin B1 complex** (Cyclin B1–CDK1) is a pivotal serine/threonine kinase complex responsible for orchestrating mitotic entry in eukaryotic cells by phosphorylating hundreds of substrate proteins. Activation of CDK1 by Cyclin B1 triggers events such as chromosome condensation, nuclear envelope breakdown, and spindle assembly—mediating the precise transition from G2 phase to mitosis. The complex localizes dynamically to centrosomes, nuclei, spindles, and kinetochores to coordinate spatial and temporal control of cell division[3][6]. Dysregulation of Cyclin B1–CDK1 is strongly linked to cancer and has made it a prominent target for anti-cancer therapy, although therapeutic intervention faces challenges related to selectivity, toxicity, and resistance mechanisms[1][5][2][7]. The complex is also known as Maturation-Promoting Factor (MPF) and exemplifies conserved biological roles across eukaryotes.
- Other names
- Cyclin B1–Cdk1 complexMaturation-Promoting Factor (MPF)CDK1–Cyclin BCCNB1–CDK1p34^cdc2^-Cyclin B1
02
Mechanism of action
Inhibition of kinase activity (ATP-competitive); Induction of cell cycle arrest at G2/M transition; Promotion of apoptosis in dividing cells
03
Biological functions
Cell cycle regulation (mitosis, meiosis)Chromosome condensationNuclear envelope breakdownSpindle assembly and chromosome segregationRegulation of gene expression and translation during mitosisProtein phosphorylation (master kinase of M-phase)Apoptosis regulationSignal transduction
04
Disease associations
Cancer (hyperactivation or dysregulation leads to uncontrolled cell proliferation and tumorigenesis; a major anti-cancer target)Developmental defects (aberrant cell division)Other proliferative disorders
05
Safety considerations
Toxicity to proliferating normal cells (e.g. bone marrow, gastrointestinal tract)Potential developmental toxicityResistance from compensatory cell cycle kinases (e.g. CDK2)Limited selectivity: inhibition may affect other cyclin-CDK family members
06
Interacting drugs
ATP-competitive CDK1 inhibitors (e.g., small molecules in development)
4 more in the full profile.
07
Biomarkers
Cyclin B1 protein expression (for proliferation, especially in cancer diagnostics)CDK1 activation state/phosphorylation statusCCNB1 gene expression
Beyond the preview
Go deeper on Cyclin-dependent kinase 1–Cyclin B1 complex (Cyclin B1–CDK1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin-dependent kinase 1–Cyclin B1 complex (Cyclin B1–CDK1).